Cite

    Daniel Fife et al.. “Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations.” Neuropsychopharmacology reports, vol. 42, no. 3, 2022, pp. 347–351. http://access.bl.uk/ark:/81055/vdc_100167556968.0x000004